Christopher Philip Ouellette

Dr. Christopher Philip Ouellette

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
COChristopher Philip Ouellette
Christopher Philip Ouellette
PSPablo J. Sánchez
Pablo J. Sánchez
ZXZhaohui Xu
Zhaohui Xu
DBDerek Blankenship
Derek Blankenship
FZFiker Zeray
Fiker Zeray
AMAsuncion Mejias
Asuncion Mejias
Congenital CMV infection (cCMVi) affects 0.5–1% of all live births worldwide, making it the leading cause of sensorineural hearing loss (SNHL) in childhood. The majority of infants with cCMVi have normal hearing at birth, but are at risk of developing late-onset SNHL. Currently, we lack reliable biomarkers to predict the development of SNHL in these infants. Here, we evaluate blood transcriptional profiles in 80 infants with cCMVi (49 symptomatic, 31 asymptomatic), enrolled in the first 3 weeks of life, and followed for 3 years to assess emergence of late-onset SNHL. The biosignatures of symptomatic and asymptomatic cCMVi are indistinguishable, suggesting that immune responses of infants with asymptomatic and symptomatic cCMVi are not different. Random forest analyses of initial samples in infants with cCMVi, irrespective of their clinical classification, identify a 16-gene classifier signature associated with the development of SNHL with 92% accuracy, suggesting its potential value as a biomarker.

24 May 2022 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
ABAngelique E Boutzoukas
Angelique E Boutzoukas
DFDaniel A Freedman
Daniel A Freedman
CKChristine Koterba
Christine Koterba
GHGarrett W Hunt
Garrett W Hunt
KMKathy Mack
Kathy Mack
COChristopher Philip Ouellette
Christopher Philip Ouellette
La Crosse virus (LACV) is the most common neuroinvasive arboviral infection in children in the United States. However, data regarding predictors of disease severity and neurologic outcome are limited. Additionally, long-term neurologic and neurobehavioral outcomes remain relatively sparse. This was a single-center, retrospective cohort study, followed by recruitment for a cross-sectional analysis of long-term neurobehavioral outcomes, among children aged 0–18 years with proven or probable LACV neuroinvasive disease (LACV-ND) between January 2009 and December 2018. Case ascertainment was assured by International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification codes cross-referenced with laboratory results detecting LACV. Demographics, diagnostics, radiographs, and outcomes were evaluated. Recruitment of patients with prior diagnosis of LACV-ND occurred from January 2020 to March 2020, with assessment performed by validated pediatric questionnaires. One-hundred fifty-two children (83 males; median age, 8 years [interquartile range, 5–11.5 years]) were diagnosed with proven (n = 61 [47%]) and probable (n = 91 [60%]) LACV-ND. Sixty-five patients (43%) had severe disease. Altered mental status (AMS) (odds ratio [OR], 6.36 [95% confidence interval {CI}, 2.03–19.95]; P = .0002) and seizures at presentation (OR, 10.31 [95% CI, 3.45–30.86]; P = .0001) were independent predictors of severe disease. Epileptiform discharges on electroencephalogram (EEG) were independently associated with epilepsy diagnosis at follow-up (OR, 13.45 [95% CI, 1.4–128.77]; P = .024). Fifty-four patients were recruited for long-term neurobehavioral follow-up, with frequent abnormal assessments identified (19%–54%) irrespective of disease severity. Severe disease was observed frequently among children with LACV-ND. Seizures and AMS at presentation were independent predictors of severe disease. EEG may help determine long-term epilepsy risk. Long-term neurobehavioral issues are frequent and likely underrecognized among children with LACV-ND.

14 August 2018 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
COChristopher Philip Ouellette
Christopher Philip Ouellette
JSJoseph R Stanek
Joseph R Stanek
ALAmy Leber
Amy Leber
MAMonica I Ardura
Monica I Ardura
A high index of suspicion for histoplasmosis is required for its diagnosis. A combination of tests, including serology, urine and blood antigen measurements, and culture, should be performed to optimize the diagnostic yield in pediatric patients suspected of having histoplasmosis.

27 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
COChristopher Philip Ouellette
Christopher Philip Ouellette
Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequent among hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients in absence of antiviral prophylaxis, and is a major cause of morbidity and mortality in these vulnerable populations. Antivirals such ganciclovir, valganciclovir, and foscarnet are the backbone therapies, however drug toxicity and antiviral resistance may render these agents suboptimal in treatment. Newer therapies such as letermovir and maribavir have offered additional approaches for antiviral prophylaxis as well as treatment of drug resistant CMV infection, though may be limited by cost, drug intolerance, or toxicity. Adoptive immunotherapy, the transfer of viral specific T-cells (VSTs), offers a new approach in treatment of drug-resistant or refractory viral infections, with early clinical trials showing promise with respect to efficacy and safety. In this review, we will discuss some of the encouraging results and challenges of widespread adoption of VSTs in care of immunocompromised patients, with an emphasis on the clinical outcomes for treatment and prophylaxis of CMV infection among high-risk patient populations.

1 November 2020 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
ADAlejandro Diaz
Alejandro Diaz
MAMonica I. Ardura
Monica I. Ardura
HWHuanyu Wang
Huanyu Wang
SAStella Antonara
Stella Antonara
COChristopher Philip Ouellette
Christopher Philip Ouellette
Osteomyelitis is a rare clinical manifestation of infection with nontuberculous mycobacteria (NTM). We report an adolescent with femoral osteomyelitis associated with prosthetic material due to an emerging pathogen, Mycobacterium goodii. Application of secA1 and 16S ribosomal RNA gene sequencing reliably determined the NTM species, enabling targeted antimicrobial therapy.

7 June 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
CBCole T Bredehoeft
Cole T Bredehoeft
COChristopher Philip Ouellette
Christopher Philip Ouellette
Pericarditis is a potential manifestation of acute histoplasmosis. Noninvasive diagnostics and imaging can be useful in defining a diagnosis. Therapy with itraconazole and corticosteroids was utilized frequently in a cohort with significant effusions at presentation.